Corpus Intelligence IC Memo — ENLOE MEDICAL CENTER 2026-04-26 06:41 UTC
IC Memo — ENLOE MEDICAL CENTER
Investment Committee Memorandum | CA | 258 beds | Grade B | EBITDA uplift $61.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ENLOE MEDICAL CENTER

CCN 050039 | BUTTE, CA | 258 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

ENLOE MEDICAL CENTER is a 258-bed suburban community hospital in BUTTE, CA with $834.4M in net patient revenue and a -0.5% operating margin. The hospital serves a payer mix of 52.7% Medicare, 4.1% Medicaid, and 43.2% commercial.

Thesis: Undervalued. Our ML models identify $61.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.5% to 6.8% (+736bps).

Net Revenue HCRIS$834.4M
Current EBITDA COMPUTED$-4.3M
Operating Margin COMPUTED-0.5%
Occupancy HCRIS72.3%
Revenue / Bed COMPUTED$3.2M
Net-to-Gross HCRIS19.5%
Distress Probability ML40.5%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
190
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -0.5% places it above the state median. Among 190 size-comparable peers (129-516 beds), the median margin is -3.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (129-516), prioritizing same-state peers. 190 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ENLOE MEDICAL CENTER (Target)CA258$834.4M-0.5%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
HOAG MEMORIAL HOSPITAL PRESBYTCA512$1.37B-3.9%
EL CAMINO HOSPITALCA388$1.34B11.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $61.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$17.5M+210bp18mo
Cost to Collect4.5%2.5%$16.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$16.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$10.2M+122bp9mo
Clean Claim Rate88.0%96.0%$534K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$17.5M
Cost to Collect
$16.7M
Denial Rate Reduction
$16.5M
A/R Days Reduction
$10.2M
Clean Claim Rate
$534K
Total EBITDA Uplift$61.4M
Current EBITDA$-4.3M
+ RCM Uplift+$61.4M
Pro Forma EBITDA$57.1M
Current Margin-0.5%
Pro Forma Margin6.8%
WC Released (1x)$32.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-6.7M$585.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-6.7M$642.0M0.00x-100.0%
Bull Case9.0x11.0x$-6.0M$842.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-6.0M$917.3M0.00x-100.0%
Bear Case11.0x10.0x$-7.3M$280.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-7.3M$306.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 190 hospitals with 129-516 beds
  • Same-state prioritization (n=191)
  • Comp margins: P25=-15.3% / P50=-3.9% / P75=4.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.